

## **DRAFT - Sample Letter – SEC Exception to Embargo Policy**

Dear Sir or Madam:

This letter is to confirm our disclosure obligations under applicable federal securities laws with regard to information included in abstract #0123 submitted for presentation at the 2011 American Society of Hematology (ASH) Annual Meeting. On November 14, XYZ Corporation will present its third-quarter results in a press release and investor presentation. It is my opinion that XYZ Corporation would not meet its obligations under Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5(b) promulgated there under without, at a minimum, disclosing a summary of the topline results (overall response rate, median duration of response, and safety information) from this Phase III study of Drug A in newly diagnosed acute myeloid leukemia patients in connection with the initial public disclosure of the results of the trial.

The co-authors of this abstract have been notified of our intent to issue a press release on November 14. Please do not hesitate to contact me if you have any questions about the statements above.

Sincerely,

John Smith, Esq.  
General Counsel